scholarly journals CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis

Oncotarget ◽  
2016 ◽  
Vol 7 (9) ◽  
pp. 10023-10036 ◽  
Author(s):  
Yang Zhao ◽  
Jing Peng ◽  
Enlong Zhang ◽  
Ning Jiang ◽  
Jiang Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Meta Analysis ◽  
Prognostic Indicator ◽  
Supportive Evidence ◽  
Cd133 Expression ◽  
Cancer Stem Cell Hypothesis

scholarly journals Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis

2015 ◽  
Vol 4 (1) ◽  
pp. 77-82 ◽  
Author(s):  
YUN-PENG SUI ◽  
XUE-PING JIAN ◽  
LI MA ◽  
GUI-ZHEN XU ◽  
HUAI-WEI LIAO ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Esophageal Carcinoma ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Stem Cell Marker ◽  
Cancer Stem Cell Marker ◽  
Cell Marker ◽  
Cd133 Expression

scholarly journals Expression of CD133 Cancer Stem Cell Marker in Melanoma: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 31 (2) ◽  
pp. 118-125 ◽  
Author(s):  
Zahra Madjd ◽  
Elham Erfani ◽  
Elmira Gheytanchi ◽  
Maziar Moradi-Lakeh ◽  
Ahmad Shariftabrizi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Meta Analysis ◽  
Stem Cell Marker ◽  
P Value ◽  
Expression Levels ◽  
Cd133 Expression ◽  
Ovid Medline ◽  
Large Heterogeneity

Background CD133-positive melanoma cells are thought to be melanoma-initiating cells with cancer stem cell (CSC) characteristics. Some researchers have reported that CD133-negative subsets can also initiate tumors, so the clinical significance of a CD133-positive subpopulation of cells in melanoma remains controversial. This systematic review was designed to assess the value of CD133 as a CSC marker in melanomas. A meta-analysis was also performed to cumulatively analyze the data on CD133 expression levels in the selected studies. Materials and Method Eligible studies were identified via an electronic search through various databases including PubMed, MEDLINE, Ovid MEDLINE, and Web of Science (from May 2005 through September 2014) using the following keywords: “CD133 or prominin-1”, “cancer stem cells”, and “melanoma”. Only articles in which CD133 antigen was detected by immunohistochemistry (IHC) were included. A meta-analysis was performed to identify any association between CD133 expression and clinical outcomes. Results Two hundred and ninety-nine melanoma cases from 5 studies were evaluated for expression levels of CD133 using IHC. Large heterogeneity was observed among the results (p<0.001, I2 = 94%). Approximately 47.9% (95% CI 23.7%-72.1%) of the studied melanoma cases had high CD133 expression. The I2 value and Q-test p value for heterogeneity were 89.0% and <0.001, respectively, and the pooled estimate of CD133 expression was 61.7% (95% CI 25.1%-98.4%). Conclusions Our findings suggest that CD133 is not yet proven to be an appropriate biomarker in identifying CSCs of melanoma. Thus, detection of CD133 in combination with other putative CSC markers may be more valuable for clinical application.

scholarly journals Immunohistochemical Detection of Cancer Stem Cell Related Markers CD44 and CD133 in Metastatic Colorectal Cancer Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Pavel Pitule ◽  
Miroslava Cedikova ◽  
Ondrej Daum ◽  
Jan Vojtisek ◽  
Ondrej Vycital ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Staining Intensity ◽  
Disease Free Interval ◽  
Cd133 Expression ◽  
Free Interval ◽  
Disease Free

Aim. The goal of this study was to semiquantitatively detect presence of cancer stem cells markers CD44 and CD133 in immunohistochemically stained paired samples of colorectal cancer (CRC) and colorectal liver metastases (CLM). Level of staining intensity was compared to clinical and pathological characteristics of tumors with the aim to identify impact of CD44 or CD133 expression on tumor behavior.Patients and Methods. Formalin fixed paraffin embedded samples from 94 patients with colorectal tumor and liver metastases were collected at Sikl’s Department of Pathology. Samples were stained by antibodies against CD44 and CD133. Presence and intensity of staining was assessed semiquantitatively by three trained researchers.Results. Patients with higher level of CD133 staining in CRC had longer disease free interval (Cox-MantelP=0.0244), whereas we found no relation between CD44 expression and overall survival or disease free interval. CD133 expression in CRC and CLM differed based on CRC grading; in case of CD44 we found differences in staining intensity in individual stages of tumor lymph node invasion.Conclusion. Effect of cancer stem cell markers on prognosis of colorectal cancer can vary depending on pathological classification of tumor, and we have shown that CD133, generally considered to be a negative marker, can bear also clinically positive prognostic information in group of patients with colorectal liver metastases.

scholarly journals Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (12) ◽  
pp. e0145164 ◽  
Author(s):  
Jinhuang Chen ◽  
Qinghua Xia ◽  
Bin Jiang ◽  
Weilong Chang ◽  
Wenzheng Yuan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Stem Cell Marker ◽  
Cancer Stem Cell Marker ◽  
Cell Marker ◽  
Aldh1 Expression

scholarly journals Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mahdieh Razmi ◽  
Roya Ghods ◽  
Somayeh Vafaei ◽  
Maryam Sahlolbei ◽  
Leili Saeednejad Zanjani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Clinical Outcomes ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Stem Cell Markers ◽  
Free Survival

Abstract Background Gastric cancer (GC) is considered one of the most lethal malignancies worldwide, which is accompanied by a poor prognosis. Although reports regarding the importance of cancer stem cell (CSC) markers in gastric cancer progression have rapidly developed over the last few decades, their clinicopathological and prognostic values in gastric cancer still remain inconclusive. Therefore, the current meta-analysis aimed to quantitatively re-evaluate the association of CSC markers expression, overall and individually, with GC patients’ clinical and survival outcomes. Methods Literature databases including PubMed, Scopus, ISI Web of Science, and Embase were searched to identify the eligible articles. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were recorded or calculated to determine the relationships between CSC markers expression positivity and overall survival (OS), disease-free survival (DFS)/relapse-free survival (RFS), disease-specific survival (DSS)/ cancer-specific survival (CSS), and clinicopathological features. Results We initially retrieved 4,425 articles, of which a total of 66 articles with 89 studies were considered as eligible for this meta-analysis, comprising of 11,274 GC patients. Overall data analyses indicated that the overexpression of CSC markers is associated with TNM stage (OR = 2.19, 95% CI 1.84–2.61, P = 0.013), lymph node metastasis (OR = 1.76, 95% CI 1.54–2.02, P < 0.001), worse OS (HR = 1.65, 95% CI 1.54–1.77, P < 0.001), poor CSS/DSS (HR = 1.69, 95% CI 1.33–2.15, P < 0.001), and unfavorable DFS/RFS (HR = 2.35, 95% CI 1.90–2.89, P < 0.001) in GC patients. However, CSC markers expression was found to be slightly linked to tumor differentiation (OR = 1.25, 95% CI 1.01–1.55, P = 0.035). Sub-analysis demonstrated a significant positive relationship between most of the individual markers, specially Gli-1, Oct-4, CD44, CD44V6, and CD133, and clinical outcomes as well as the reduced survival, whereas overexpression of Lgr-5, Nanog, and sonic hedgehog (Shh) was not found to be related to the majority of clinical outcomes in GC patients. Conclusion The expression of CSC markers is mostly associated with worse outcomes in patients with GC, both overall and individual. The detection of a combined panel of CSC markers might be appropriate as a prognostic stratification marker to predict tumor aggressiveness and poor prognosis in patients with GC, which probably results in identifying novel potential targets for therapeutic approaches.

scholarly journals Colorectal Cancer Stem Cell States Uncovered by Simultaneous Single‐Cell Analysis of Transcriptome and Telomeres

2021 ◽  
Vol 8 (8) ◽  
pp. 2004320
Author(s):  
Hua Wang ◽  
Peng Gong ◽  
Tong Chen ◽  
Shan Gao ◽  
Zhenfeng Wu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Single Cell ◽  
Single Cell Analysis ◽  
Cell Analysis

scholarly journals Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor

2020 ◽  
Vol 123 (6) ◽  
pp. 955-964
Author(s):  
Kazuya Iwamoto ◽  
Hidekazu Takahashi ◽  
Daisuke Okuzaki ◽  
Hideo Osawa ◽  
Takayuki Ogino ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Prostaglandin E2 ◽  
Cell Expansion ◽  
Stem Cell Expansion ◽  
Prostaglandin E2 Receptor
Sign in / Sign up

Export Citation Format

Share Document